The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

High throughput genotyping of oncogenic human papilloma viruses using MALDI-TOF mass spectrometry.

Author

Summary, in English

Background: Human papilloma virus (HPV) is the major cause of cervical cancer. Use of HPV genotyping in cervical screening programs and for monitoring the effectiveness of HPV vaccination programs requires access to economical, high-throughput technology.



Methods: We used the Sequenom MassARRAY platform to develop a high-throughput mass spectrometric (MS) method for detecting 14 specific oncogenic HPV genotypes in multiplex PCR products. We compared results from 532 cervical cell samples to the comparison method, reverse dot blot hybridization (RDBH).



Results: The MS method detected all samples found positive by RDBH. In addition, the MS method identified 5 cases of cervical disease (cervical intraepithelial neoplasia of grade I or higher) that RDBH analysis had missed. Discrepancies in specific genotypes were noted in 20 samples, all positive by MS, with an overall concordance of {kappa} = 0.945.



Conclusions: The MS high-throughput method, with a processing capacity of 10 x 384 samples within 2 working days and at a consumables cost of about US$2 per sample, performed as well as or better than the comparison method.

Publishing year

2008

Language

English

Pages

86-92

Publication/Series

Clinical Chemistry

Volume

54

Issue

1

Document type

Journal article

Publisher

American Association for Clinical Chemistry

Topic

  • Biochemistry and Molecular Biology

Status

Published

Research group

  • Clinical Microbiology, Malmö
  • Clinical Chemistry, Malmö

ISBN/ISSN/Other

  • ISSN: 0009-9147